

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
7 March 2002 (07.03.2002)

PCT


(10) International Publication Number  
WO 02/18613 A1

- (51) International Patent Classification<sup>7</sup>: C12P 13/12, C07K 14/34, C12N 9/00, 1/21, 15/10, 15/63, C12Q 1/68, A23L 1/305 // (C12P 13/12, C12R 1:15)
- (21) International Application Number: PCT/EP01/08223
- (22) International Filing Date: 17 July 2001 (17.07.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
100 43 334.0 2 September 2000 (02.09.2000) DE  
101 09 690.9 28 February 2001 (28.02.2001) DE
- (71) Applicant: DEGUSSA AG [DE/DE]; Bennigsenplatz 1, 40474 Düsseldorf (DE).
- (72) Inventors: MÖCKEL, Bettina; Benrodestrasse 35, 40597 Düsseldorf (DE). PFEFFERLE, Walter; Jahnstrasse 33, 33790 Halle (Westf.) (DE). HUTHMACHER, Klaus; Lärchenweg 18, 63584 Gelnhausen (DE). RÜCKERT, Christian; Agnesstrasse 49, 33335 Gütersloh (DE). KALINOWSKI, Jörn; Lenbachstrasse 19, 33615 Bielefeld (DE). PÜHLER, Alfred; Am Waldschlösschen 2, 33739 Bielefeld (DE). BINDER, Michael; Kalberkamp 28, 33803 Steinhagen (Westf.) (DE). GREISSINGER, Dieter; Augasse 1f, 61194 Niddatal (DE). THIERBACH, Georg; Gunststrasse 21, 33613 Bielefeld (DE).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

[Continued on next page]

(54) Title: NUCLEOTIDE SEQUENCES WHICH CODE FOR THE metY GENE

Plasmid pCREmetY



(57) Abstract: The invention relates to an isolated polynucleotide comprising a polynucleotide sequence chosen from the group consisting of a) polynucleotide which is identical to the extent of at least 70 % to a polynucleotide which codes for a polypeptide which comprises the amino acid sequence of SEQ ID No. 2, b) polynucleotide which codes for a polypeptide which comprises an amino acid sequence which is identical to the extent of at least 70 % to the amino acid sequence of SEQ ID No. 2, c) polynucleotide which is complementary to the polynucleotides of a) or b), and d) polynucleotide comprising at least 15 successive nucleotides of the polynucleotide sequence of a), b) or c), and a process for the fermentative preparation of L-amino acids using coryneform bacteria in which at least the metY gene coding for O-acetyl-L-homoserine-sulphydrylase (EC 4.2.99.10) is present in enhanced form, and the use of the polynucleotides which comprise the polynucleotide sequences according to the invention as hybridization probes.

WO 02/18613 A1

Best Available Copy



(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**

— *with international search report*

## Nucleotide sequences which code for the metY gene

### Field of the Invention

The invention provides nucleotide sequences from coryneform bacteria which code for the metY gene and a process for the fermentative preparation of amino acids, in particular L-lysine and L-methionine, using bacteria in which at least the metY gene is enhanced.

### Prior Art

L-Amino acids, in particular L-lysine and L-methionine, are used in human medicine and in the pharmaceuticals industry, in the foodstuffs industry and very particularly in animal nutrition.

It is known that amino acids are prepared by fermentation from strains of coryneform bacteria, in particular *Corynebacterium glutamicum*. Because of their great importance, work is constantly being undertaken to improve the preparation processes. Improvements to the process can relate to fermentation measures, such as, for example, stirring and supply of oxygen, or the composition of the nutrient media, such as, for example, the sugar concentration during the fermentation, or the working up to the product form by, for example, ion exchange chromatography, or the intrinsic output properties of the microorganism itself.

Methods of mutagenesis, selection and mutant selection are used to improve the output properties of these microorganisms. Strains which are resistant to antimetabolites or are auxotrophic for metabolites of regulatory importance and produce amino acids are obtained in this manner.

Methods of the recombinant DNA technique have also been employed for some years for improving the strain of

Corynebacterium strains which produce L-amino acid, by amplifying individual amino acid biosynthesis genes and investigating the effect on the amino acid production.

#### Object of the Invention

- 5 The inventors had the object of providing new measures for improved fermentative preparation of amino acids, in particular L-lysine and L-methionine.

#### Summary of the Invention

- Where L-amino acids or amino acids are mentioned in the following, this means one or more amino acids, including their salts, chosen from the group consisting of L-asparagine, L-threonine, L-serine, L-glutamate, L-glycine, L-alanine, L-cysteine, L-valine, L-methionine, L-isoleucine, L-leucine, L-tyrosine, L-phenylalanine, L-histidine, L-lysine, L-tryptophan and L-arginine.

When L-lysine or lysine are mentioned in the following, not only the bases but also the salts, such as e.g. lysine monohydrochloride or lysine sulfate, are meant by this.

- When L-methionine or methionine are mentioned in the following, the salts, such as e.g. methionine hydrochloride or methionine sulfate, are also meant by this.

- The invention provides an isolated polynucleotide from coryneform bacteria, comprising a polynucleotide sequence which codes for the metY gene, chosen from the group consisting of

- a) polynucleotide which is identical to the extent of at least 70% to a polynucleotide which codes for a polypeptide which comprises the amino acid sequence of SEQ ID No. 2,
- b) polynucleotide which codes for a polypeptide which comprises an amino acid sequence which is identical to

the extent of at least 70% to the amino acid sequence of SEQ ID No. 2,

- c) polynucleotide which is complementary to the polynucleotides of a) or b), and
- 5 d) polynucleotide comprising at least 15 successive nucleotides of the polynucleotide sequence of a), b) or c),

the polypeptide preferably having the activity of O-acetylhomoserine sulphydrylase.

10 The invention also provides the above-mentioned polynucleotide, this preferably being a DNA which is capable of replication, comprising:

- (i) the nucleotide sequence shown in SEQ ID No. 1, or
- (ii) at least one sequence which corresponds to  
15 sequence (i) within the range of the degeneration of the genetic code, or
- (iii) at least one sequence which hybridizes with the sequence complementary to sequence (i) or (ii), and optionally
- 20 (iv) sense mutations of neutral function in (i).

The invention also provides

a polynucleotide comprising the nucleotide sequence as shown in SEQ ID No. 1;

a polynucleotide which codes for a polypeptide which  
25 comprises the amino acid sequence as shown in SEQ ID No. 2;

a vector containing the DNA sequence of *C. glutamicum* which codes for the metY gene, deposited in accordance with

the Budapest Treaty in *Corynebacterium glutamicum* as pCREmetY on 21.06.2000 under DSM 13556

and coryneform bacteria in which the metY gene is present in enhanced form, in particular by the vector pCREmetY.

- 5 The invention also provides polynucleotides which substantially comprise a polynucleotide sequence, which are obtainable by screening by means of hybridization of a corresponding gene library of a coryneform bacterium, which comprises the complete gene or parts thereof, with a probe
- 10 which comprises the sequence of the polynucleotide according to the invention according to SEQ ID No.1 or a fragment thereof, and isolation of the polynucleotide sequence mentioned.

#### Detailed Description of the Invention

- 15 Polynucleotides which comprise the sequences according to the invention are suitable as hybridization probes for RNA, cDNA and DNA, in order to isolate, in the full length, nucleic acids or polynucleotides or genes which code for O-acetylhomoserine sulfhydrylase or to isolate those nucleic
- 20 acids or polynucleotides or genes which have a high similarity of sequence with that of the O-acetylhomoserine sulfhydrylase.

- Polynucleotides which comprise the sequences according to the invention are furthermore suitable as primers with the
- 25 aid of which DNA of genes which code for O-acetylhomoserine sulfhydrylase can be prepared by the polymerase chain reaction (PCR).

- Such oligonucleotides which serve as probes or primers comprise at least 30, preferably at least 20, very
- 30 particularly preferably at least 15 successive nucleotides. Oligonucleotides which have a length of at least 40 or 50 nucleotides are also suitable. Oligonucleotides with a

length of at least 100, 150, 200, 250 or 300 nucleotides are optionally also suitable.

"Isolated" means separated out of its natural environment.

5 "Polynucleotide" in general relates to polyribonucleotides and polydeoxyribonucleotides, it being possible for these to be non-modified RNA or DNA or modified RNA or DNA.

10 The polynucleotides according to the invention include a polynucleotide according to SEQ ID No. 1 or a fragment prepared therefrom and also those which are at least 70%, preferably at least 80% and in particular at least 90% to 95% identical to the polynucleotide according to SEQ ID No. 1 or a fragment prepared therefrom.

15 "Polypeptides" are understood as meaning peptides or proteins which comprise two or more amino acids bonded via peptide bonds.

20 The polypeptides according to the invention include a polypeptide according to SEQ ID No. 2, in particular those with the biological activity of O-acetylhomoserine sulphydrylase, and also those which are at least 70%, preferably at least 80%, and in particular which are at least 90% to 95% identical to the polypeptide according to SEQ ID No. 2 and have the activity mentioned.

25 The invention moreover provides a process for the fermentative preparation of amino acids, in particular L-lysine and L-methionine, using coryneform bacteria which in particular already produce amino acids, and in which at least the nucleotide sequences which code for the metY gene are enhanced, in particular over-expressed.

30 The term "enhancement" in this connection describes the increase in the intracellular activity of one or more enzymes in a microorganism which are coded by the corresponding DNA, for example by increasing the number of

copies of the gene or genes, using a potent promoter or using a gene which codes for a corresponding enzyme having a high activity, and optionally combining these measures.

By enhancement measures, in particular over-expression, the activity or concentration of the corresponding protein is in general increased by at least 10%, 25%, 50%, 75%, 100%, 150%, 200%, 300%, 400% or 500%, up to a maximum of 1000% or 2000%, based on the starting microorganism.

The microorganisms which the present invention provides can prepare L-amino acids, in particular L-lysine and L-methionine, from glucose, sucrose, lactose, fructose, maltose, molasses, starch, cellulose or from glycerol and ethanol. They can be representatives of coryneform bacteria, in particular of the genus *Corynebacterium*. Of the genus *Corynebacterium*, there may be mentioned in particular the species *Corynebacterium glutamicum*, which is known among experts for its ability to produce L-amino acids.

Suitable strains of the genus *Corynebacterium*, in particular of the species *Corynebacterium glutamicum* (*C. glutamicum*), are in particular the known wild-type strains

*Corynebacterium glutamicum* ATCC13032

*Corynebacterium acetoglutamicum* ATCC15806.

*Corynebacterium acetoacidophilum* ATCC13870

*Corynebacterium thermoaminogenes* FERM BP-1539

*Corynebacterium melassecola* ATCC17965

*Brevibacterium flavum* ATCC14067

*Brevibacterium lactofermentum* ATCC13869 and

*Brevibacterium divaricatum* ATCC14020

or L-lysine-producing mutants or strains prepared therefrom, such as, for example

*Corynebacterium glutamicum* FERM-P 1709

*Brevibacterium flavum* FERM-P 1708



Brevibacterium lactofermentum FERM-P 1712  
Corynebacterium glutamicum FERM-P 6463  
Corynebacterium glutamicum FERM-P 6464 and  
Corynebacterium glutamicum DSM5715.

- 5 or L-methionine-producing mutants or strains prepared therefrom, such as, for example

Corynebacterium glutamicum ATCC21608.

The new metY gene from C. glutamicum which codes for the enzyme O-acetylhomoserine sulphydrylase (EC 4.2.99.10) has  
10 been isolated.

To isolate the metY gene or also other genes of C. glutamicum, a gene library of this microorganism is first set up in Escherichia coli (E. coli). The setting up of gene libraries is described in generally known textbooks and handbooks. The textbook by Winnacker: Gene und Klone,  
15 Eine Einführung in die Gentechnologie (Verlag Chemie, Weinheim, Germany, 1990), or the handbook by Sambrook et al.: Molecular Cloning, A Laboratory Manual (Cold Spring Harbor Laboratory Press, 1989) may be mentioned as an  
20 example. A well-known gene library is that of the E. coli K-12 strain W3110 set up in  $\lambda$  vectors by Kohara et al. (Cell 50, 495-508 (1987)). Bathe et al. (Molecular and General Genetics, 252:255-265, 1996) describe a gene library of C. glutamicum ATCC13032, which was set up with  
25 the aid of the cosmid vector SuperCos I (Wahl et al., 1987, Proceedings of the National Academy of Sciences USA, 84:2160-2164) in the E. coli K-12 strain NM554 (Raleigh et al., 1988, Nucleic Acids Research 16:1563-1575).

Börmann et al. (Molecular Microbiology 6(3), 317-326)  
30 (1992)) in turn describe a gene library of C. glutamicum ATCC13032 using the cosmid pHC79 (Hohn and Collins, Gene 11, 291-298 (1980)). To prepare a gene library of C. glutamicum in E. coli it is also possible to use plasmids

such as pBR322 (Bolivar, Life Sciences, 25, 807-818 (1979)) or pUC9 (Vieira et al., 1982, Gene, 19:259-268). Suitable hosts are, in particular, those E. coli strains which are restriction- and recombination-defective. An example of these is the strain DH5amcr, which has been described by Grant et al. (Proceedings of the National Academy of Sciences USA, 87 (1990) 4645-4649). The long DNA fragments cloned with the aid of cosmids can in turn be subcloned in the usual vectors suitable for sequencing and then sequenced, as is described e.g. by Sanger et al. (Proceedings of the National Academy of Sciences of the United States of America, 74:5463-5467, 1977).

The resulting DNA sequences can then be investigated with known algorithms or sequence analysis programs, such as e.g. that of Staden (Nucleic Acids Research 14, 217-232(1986)), that of Marck (Nucleic Acids Research 16, 1829-1836 (1988)) or the GCG program of Butler (Methods of Biochemical Analysis 39, 74-97 (1998)).

The new DNA sequence of C. glutamicum which codes for the metY gene and which, as SEQ ID No. 1, is a constituent of the present invention has been found. The amino acid sequence of the corresponding protein has furthermore been derived from the present DNA sequence by the methods described above. The resulting amino acid sequence of the metY gene product is shown in SEQ ID No. 2.

Coding DNA sequences which result from SEQ ID No. 1 by the degeneracy of the genetic code are also a constituent of the invention. In the same way, DNA sequences which hybridize with SEQ ID No. 1 or parts of SEQ ID No. 1 are a constituent of the invention. Conservative amino acid exchanges, such as e.g. exchange of glycine for alanine or of aspartic acid for glutamic acid in proteins, are furthermore known among experts as "sense mutations" which do not lead to a fundamental change in the activity of the protein, i.e. are of neutral function. It is furthermore

known that changes on the N and/or C terminus of a protein cannot substantially impair or can even stabilize the function thereof. Information in this context can be found by the expert, inter alia, in Ben-Bassat et al. (Journal of Bacteriology 169:751-757 (1987)), in O'Regan et al. (Gene 77:237-251 (1989)), in Sahin-Toth et al. (Protein Sciences 3:240-247 (1994)), in Hochuli et al. (Bio/Technology 6:1321-1325 (1988)) and in known textbooks of genetics and molecular biology. Amino acid sequences which result in a corresponding manner from SEQ ID No. 2 are also a constituent of the invention.

In the same way, DNA sequences which hybridize with SEQ ID No. 1 or parts of SEQ ID No. 1 are a constituent of the invention. Finally, DNA sequences which are prepared by the polymerase chain reaction (PCR) using primers which result from SEQ ID No. 1 are a constituent of the invention. Such oligonucleotides typically have a length of at least 15 nucleotides.

Instructions for identifying DNA sequences by means of hybridization can be found by the expert, inter alia, in the handbook "The DIG System Users Guide for Filter Hybridization" from Boehringer Mannheim GmbH (Mannheim, Germany, 1993) and in Liebl et al. (International Journal of Systematic Bacteriology (1991), 41: 255-260). The hybridization takes place under stringent conditions, that is to say only hybrids in which the probe and target sequence, i.e. the polynucleotides treated with the probe, are at least 70% identical are formed. It is known that the stringency of the hybridization, including the washing steps, is influenced or determined by varying the buffer composition, the temperature and the salt concentration. The hybridization reaction is preferably carried out under a relatively low stringency compared with the washing steps (Hybaid Hybridisation Guide, Hybaid Limited, Teddington, UK, 1996).

A 5x SSC buffer at a temperature of approx. 50 - 68°C, for example, can be employed for the hybridization reaction. Probes can also hybridize here with polynucleotides which are less than 70% identical to the sequence of the probe.

5 Such hybrids are less stable and are removed by washing under stringent conditions. This can be achieved, for example, by lowering the salt concentration to 2x SSC and optionally subsequently 0.5x SSC (The DIG System User's Guide for Filter Hybridisation, Boehringer Mannheim, Mannheim, Germany, 1995) a temperature of approx. 50 - 68°C

10 being established. It is optionally possible to lower the salt concentration to 0.1x SSC. Polynucleotide fragments which are, for example, at least 70% or at least 80% or at least 90% to 95% identical to the sequence of the probe

15 employed can be isolated by increasing the hybridization temperature stepwise from 50 to 68°C in steps of approx. 1 - 2°C. Further instructions on hybridization are obtainable on the market in the form of so-called kits (e.g. DIG Easy Hyb from Roche Diagnostics GmbH, Mannheim, Germany, Catalogue No. 1603558).

20

Instructions for amplification of DNA sequences with the aid of the polymerase chain reaction (PCR) can be found by the expert, inter alia, in the handbook by Gait: Oligonucleotide synthesis: A Practical Approach (IRL Press, Oxford, UK, 1984) and in Newton and Graham: PCR (Spektrum Akademischer Verlag, Heidelberg, Germany, 1994).

25

It has been found that coryneform bacteria produce amino acids, in particular L-lysine and L-methionine, in an improved manner after over-expression of the metY gene, optionally in combination with the metA gene.

30

To achieve an over-expression, the number of copies of the corresponding genes can be increased, or the promoter and regulation region or the ribosome binding site upstream of the structural gene can be mutated. Expression cassettes which are incorporated upstream of the structural gene act

35

in the same way. By inducible promoters, it is additionally possible to increase the expression in the course of fermentative L-lysine and L-methionine production. The expression is likewise improved by  
5 measures to prolong the life of the m-RNA. Furthermore, the enzyme activity is also increased by preventing the degradation of the enzyme protein. The genes or gene constructs can either be present in plasmids with a varying number of copies, or can be integrated and amplified in the  
10 chromosome. Alternatively, an over-expression of the genes in question can furthermore be achieved by changing the composition of the media and the culture procedure.

Instructions in this context can be found by the expert, inter alia, in Martin et al. (Bio/Technology 5, 137-146  
15 (1987)), in Guerrero et al. (Gene 138, 35-41 (1994)), Tsuchiya and Morinaga (Bio/Technology 6, 428-430 (1988)), in Eikmanns et al. (Gene 102, 93-98 (1991)), in European Patent Specification 0 472 869, in US Patent 4,601,893, in Schwarzer and Pühler (Bio/Technology 9, 84-87 (1991)), in  
20 Reinscheid et al. (Applied and Environmental Microbiology 60, 126-132 (1994)), in LaBarre et al. (Journal of Bacteriology 175, 1001-1007 (1993)), in Patent Application WO 96/15246, in Malumbres et al. (Gene 134, 15 - 24 (1993)), in Japanese Laid-Open Specification JP-A-10-  
25 229891, in Jensen and Hammer (Biotechnology and Bioengineering 58, 191-195 (1998)), in Makrides (Microbiological Reviews 60:512-538 (1996)) and in known textbooks of genetics and molecular biology.

By way of example, for enhancement the metY gene according  
30 to the invention was over-expressed with the aid of episomal plasmids. Suitable plasmids are those which are replicated in coryneform bacteria. Numerous known plasmid vectors, such as e.g. pZ1 (Menkel et al., Applied and Environmental Microbiology (1989) 64: 549-554), pEKEx1  
35 (Eikmanns et al., Gene 102:93-98 (1991)) or pHS2-1 (Sonnen

et al., Gene 107:69-74 (1991)) are based on the cryptic plasmids pHM1519, pBL1 or pGA1. Other plasmid vectors, such as e.g. those based on pCG4 (US-A 4,489,160), or pNG2 (Serwold-Davis et al., FEMS Microbiology Letters 66, 119-124 (1990)), or pAG1 (US-A 5,158,891), can be used in the same manner.

Examples of such plasmid vectors are shown in figures 1 and 2.

Plasmid vectors which are furthermore suitable are also those with the aid of which the process of gene amplification by integration into the chromosome can be used, as has been described, for example, by Reinscheid et al. (Applied and Environmental Microbiology 60, 126-132 (1994)) for duplication or amplification of the hom-thrB operon. In this method, the complete gene is cloned in a plasmid vector which can replicate in a host (typically E. coli), but not in C. glutamicum. Possible vectors are, for example, pSUP301 (Simon et al., Bio/Technology 1, 784-791 (1983)), pK18mob or pK19mob (Schäfer et al., Gene 145, 69-73 (1994)), pGEM-T (Promega corporation, Madison, WI, USA), pCR2.1-TOPO (Shuman (1994). Journal of Biological Chemistry 269:32678-84; US-A 5,487,993), pCR@Blunt (Invitrogen, Groningen, Holland; Bernard et al., Journal of Molecular Biology, 234: 534-541 (1993)), pEM1 (Schrumpf et al, 1991, Journal of Bacteriology 173:4510-4516) or pBGS8 (Spratt et al., 1986, Gene 41: 337-342). The plasmid vector which contains the gene to be amplified is then transferred into the desired strain of C. glutamicum by conjugation or transformation. The method of conjugation is described, for example, by Schäfer et al. (Applied and Environmental Microbiology 60, 756-759 (1994)). Methods for transformation are described, for example, by Thierbach et al. (Applied Microbiology and Biotechnology 29, 356-362 (1988)), Dunican and Shivnan (Bio/Technology 7, 1067-1070 (1989)) and Tauch et al. (FEMS Microbiological Letters 123,

343-347 (1994)). After homologous recombination by means of a "cross over" event, the resulting strain contains at least two copies of the gene in question.

In addition, it may be advantageous for the production of amino acids, in particular L-lysine and L-methionine, to enhance one or more enzymes of the particular biosynthesis pathway, of glycolysis, of anaplerosis, or of amino acid export, in addition to the metY gene.

Thus, for the preparation of L-lysine, one or more genes chosen from the group consisting of

Thus, for example, for the preparation of L-lysine one or more genes chosen from the group consisting of

- the gap gene which codes for glyceraldehyde 3-phosphate dehydrogenase (Eikmanns (1992), Journal of Bacteriology 174:6076-6086),
- the tpi gene which codes for triose phosphate isomerase (Eikmanns (1992), Journal of Bacteriology 174:6076-6086),
- the pgk gene which codes for 3-phosphoglycerate kinase (Eikmanns (1992), Journal of Bacteriology 174:6076-6086),
- the pyc gene which codes for pyruvate carboxylase (DE-A-198 31 609),
- the lysC gene which codes for a feed-back resistant aspartate kinase (ACCESSION NUMBER P26512),

can be enhanced, in particular over-expressed.

Thus, for example, for the preparation of L-methionine one or more genes chosen from the group consisting of

- the gap gene which codes for glyceraldehyde 3-phosphate dehydrogenase (Eikmanns (1992), Journal of Bacteriology 174:6076-6086),

- the tpi gene which codes for triose phosphate isomerase (Eikmanns (1992), Journal of Bacteriology 174:6076-6086),
  - the pgk gene which codes for 3-phosphoglycerate kinase (Eikmanns (1992), Journal of Bacteriology 174:6076-6086),
  - 5 • the pyc gene which codes for pyruvate carboxylase (DE-A-198 31 609),
  - the lysC gene which codes for a feed-back resistant aspartate kinase (ACCESSION NUMBER P26512),
  - 10 • the metA gene which codes for homoserine O-acetyltransferase (ACCESSION Number AF052652),
  - the metB gene which codes for cystathionine-gamma-synthase (ACCESSION Number AF126953),
  - the aecD gene which codes for cystathionine-gamma-lyase (ACCESSION Number M89931).
  - 15 • the glyA gene which codes for serine hydroxymethyltransferase (JP-A-08107788),
- can be enhanced, in particular over-expressed, additional enhancement of metA being particularly preferred.

It may furthermore be advantageous for the production of L-lysine, in addition to the enhancement of the metY gene, for one or more genes chosen from the group consisting of

- the pck gene which codes for phosphoenol pyruvate carboxykinase (DE 199 50 409.1; DSM 13047),
- the pgi gene which codes for glucose 6-phosphate isomerase (US 09/396,478, DSM 12969),
- 25 • the poxB gene which codes for pyruvate oxidase (DE: 1995 1975.7; DSM 13114)



to be attenuated, in particular for the expression thereof to be reduced.

It may furthermore be advantageous for the production of L-methionine, in addition to the enhancement of the metY

5 gene, for one or more genes chosen from the group consisting of

- the pck gene which codes for phosphoenol pyruvate carboxykinase (DE 199 50 409.1; DSM 13047),
- 10 • the pgi gene which codes for glucose 6-phosphate isomerase (US 09/396,478, DSM 12969),
- the poxB gene which codes for pyruvate oxidase (DE: 1995 1975.7; DSM 13114)
- the thrB gene which codes for homoserine kinase (ACCESSION Number P08210),
- 15 • the ilvA gene which codes for threonine dehydratase (ACCESSION Number Q04513),
- the thrC gene which codes for threonine synthase (ACCESSION Number P23669),
- 20 • the ddh gene which codes for meso-diaminopimelate D-dehydrogenase (ACCESSION Number Y00151),

to be attenuated, in particular for the expression thereof to be reduced.

The term "enhancement" in this connection describes the increase in the intracellular activity of one or more  
25 enzymes (proteins) in a microorganism which are coded by the corresponding DNA, for example by increasing the number of copies of the gene or genes, using a potent promoter or using a gene or allele which codes for a corresponding enzyme (protein) having a high activity, and optionally  
30 combining these measures.

By enhancement measures, in particular over-expression, the activity or concentration of the corresponding protein is in general increased by at least 10%, 25%, 50%, 75%, 100%, 150%, 200%, 300%, 400% or 500%, up to a maximum of 1000% or 2000%, based on the starting microorganism.

In addition to over-expression of the metY gene, optionally in combination with the metA gene it may furthermore be advantageous, for the production of amino acids, in particular L-lysine and L-methionine, to eliminate

undesirable side reactions, (Nakayama: "Breeding of Amino Acid Producing Micro-organisms", in: Overproduction of Microbial Products, Krumphanzl, Sikyta, Vanek (eds.), Academic Press, London, UK, 1982).

The microorganisms prepared according to the invention can be cultured continuously or discontinuously in the batch process (batch culture) or in the fed batch (feed process) or repeated fed batch process (repetitive feed process) for the purpose of production of amino acids, in particular L-lysine and L-methionine. A summary of known culture methods is described in the textbook by Chmiel (Bioprozesstechnik 1. Einführung in die Bioverfahrenstechnik (Gustav Fischer Verlag, Stuttgart, 1991)) or in the textbook by Storhas (Bioreaktoren und periphere Einrichtungen (Vieweg Verlag, Braunschweig/Wiesbaden, 1994)).

The culture medium to be used must meet the requirements of the particular strains in a suitable manner. Descriptions of culture media for various microorganisms are contained in the handbook "Manual of Methods for General Bacteriology" of the American Society for Bacteriology (Washington D.C., USA, 1981).

Sugars and carbohydrates, such as e.g. glucose, sucrose, lactose, fructose, maltose, molasses, starch and cellulose, oils and fats, such as e.g. soya oil, sunflower oil,

- groundnut oil and coconut fat, fatty acids, such as e.g. palmitic acid, stearic acid and linoleic acid; alcohols, such as e.g. glycerol and ethanol, and organic acids, such as e.g. acetic acid, can be used as the source of carbon.
- 5 These substance can be used individually or as a mixture.

- Organic nitrogen-containing compounds, such as peptones, yeast extract, meat extract, malt extract, corn steep liquor, soya bean flour and urea, or inorganic compounds, such as ammonium sulfate, ammonium chloride, ammonium
- 10 phosphate, ammonium carbonate and ammonium nitrate, can be used as the source of nitrogen. The sources of nitrogen can be used individually or as a mixture.

- Phosphoric acid, potassium dihydrogen phosphate or dipotassium hydrogen phosphate or the corresponding sodium-
- 15 containing salts can be used as the source of phosphorus.

- Organic and inorganic sulfur-containing compounds, such as, for example, sulfides, sulfites, sulfates and thiosulfates, can be used as a source of sulfur, in particular for the preparation of sulfur-containing amino acids.
- 20 The culture medium must furthermore comprise salts of metals, such as e. g. magnesium sulfate or iron sulfate, which are necessary for growth. Finally, essential growth substances, such as amino acids and vitamins, can be employed in addition to the above-mentioned substances.
- 25 Suitable precursors can moreover be added to the culture medium. The starting substances mentioned can be added to the culture in the form of a single batch, or can be fed in during the culture in a suitable manner.

- Basic compounds, such as sodium hydroxide, potassium
- 30 hydroxide, ammonia or aqueous ammonia, or acid compounds, such as phosphoric acid or sulfuric acid, can be employed in a suitable manner to control the pH. Antifoams, such as e.g. fatty acid polyglycol esters, can be employed to

control the development of foam. Suitable substances having a selective action, such as e.g. antibiotics, can be added to the medium to maintain the stability of plasmids. To maintain aerobic conditions, oxygen or oxygen-containing gas mixtures, such as e.g. air, are introduced into the culture. The temperature of the culture is usually 20°C to 45°C, and preferably 25°C to 40°C. Culturing is continued until a maximum of the desired product has formed. This target is usually reached within 10 hours to 160 hours.

10 The fermentation broths obtained in this way, in particular containing L-methionine, usually have a dry weight of 7.5 to 25 wt.% and contain L-methionine. It is furthermore also advantageous if the fermentation is conducted in a sugar-limited procedure at least at the end, but in particular over at least 30% of the duration of the fermentation. That is to say, the concentration of utilizable sugar in the fermentation medium is reduced to  $\geq 0$  to 3 g/l during this period.

20 The fermentation broth prepared in this manner, in particular containing L-methionine, is then further processed. Depending on requirements, all or some of the biomass can be removed from the fermentation broth by separation methods, such as e.g. centrifugation, filtration, decanting or a combination thereof, or it can be left completely in this. This broth is then thickened or concentrated by known methods, such as e.g. with the aid of a rotary evaporator, thin film evaporator, falling film evaporator, by reverse osmosis, or by nanofiltration. This concentrated fermentation broth can then be worked up by methods of freeze drying, spray drying, spray granulation or by other processes to give a preferably free-flowing, finely divided powder.

This free-flowing, finely divided powder can then in turn be converted by suitable compacting or granulating processes into a coarse-grained, readily free-flowing,

storable and largely dust-free product. In the granulation or compacting it is advantageous to employ conventional organic or inorganic auxiliary substances or carriers, such as starch, gelatin, cellulose derivatives or similar substances, such as are conventionally used as binders, gelling agents or thickeners in foodstuffs or feedstuffs processing, or further substances, such as, for example, silicas, silicates or stearates.

"Free-flowing" is understood as meaning powders which flow unimpeded out of the vessel with the opening of 5 mm (millimeters) of a series of glass outflow vessels with outflow openings of various sizes (Klein, Seifen, Öle, Fette, Wachse 94, 12 (1968)).

As described here, "finely divided" means a powder with a predominant content ( $> 50\%$ ) with a particle size of 20 to 200  $\mu\text{m}$  diameter. "Coarse-grained" means products with a predominant content ( $> 50\%$ ) with a particle size of 200 to 2000  $\mu\text{m}$  diameter. In this context, "dust-free" means that the product contains only small contents ( $< 5\%$ ) with particle sizes of less than 20  $\mu\text{m}$  diameter. The particle size determination can be carried out with methods of laser diffraction spectrometry. The corresponding methods are described in the textbook on "Teilchengrößenmessung in der Laborpraxis" by R. H. Müller and R. Schuhmann, Wissenschaftliche Verlagsgesellschaft Stuttgart (1996) or in the textbook "Introduction to Particle Technology" by M. Rhodes, Verlag Wiley & Sons (1998).

"Storable" in the context of this invention means a product which can be stored for up to 120 days, preferably up to 52 weeks, particularly preferably 60 months, without a substantial loss ( $< 5\%$ ) of methionine occurring.

Alternatively, however, the product can be absorbed on to an organic or inorganic carrier substance which is known and conventional in feedstuffs processing, such as, for

example, silicas, silicates, grits, brans, meals, starches, sugars or others, and/or mixed and stabilized with conventional thickeners or binders. Use examples and processes in this context are described in the literature  
5 (Die Mühle + Mischfuttertechnik 132 (1995) 49, page 817).

Finally, the product can be brought into a state in which it is stable to digestion by animal stomachs, in particular the stomach of ruminants, by coating processes ("coating") using film-forming agents, such as, for example, metal  
10 carbonates, silicas, silicates, alginates, stearates, starches, gums and cellulose ethers, as described in DE-C-4100920.

If the biomass is separated off during the process, further inorganic solids, for example added during the  
15 fermentation, are in general removed. In addition, the animal feedstuffs additive according to the invention comprises at least the predominant proportion of the further substances, in particular organic substances, which are formed or added and are present in solution in the  
20 fermentation broth, where these have not been separated off by suitable processes.

In one aspect of the invention, the biomass can be separated off to the extent of up to 70%, preferably up to 80%, preferably up to 90%, preferably up to 95%, and  
25 particularly preferably up to 100%. In another aspect of the invention, up to 20% of the biomass, preferably up to 15%, preferably up to 10%, preferably up to 5%, particularly preferably no biomass is separated off.

These organic substances include organic by-products which  
30 are optionally produced, in addition to the L-methionine, and optionally discharged by the microorganisms employed in the fermentation. These include L-amino acids chosen from the group consisting of L-lysine, L-valine, L-threonine, L-alanine or L-tryptophan. They include vitamins chosen from

the group consisting of vitamin B1 (thiamine), vitamin B2 (riboflavin), vitamin B5 (pantothenic acid), vitamin B6 (pyridoxine), vitamin B12 (cyanocobalamin), nicotinic acid/nicotinamide and vitamin E (tocopherol). They include  
5 furthermore organic acids which carry one to three carboxyl groups, such as, for example, acetic acid, lactic acid, citric acid, malic acid or fumaric acid. Finally, they also include sugars, such as, for example, trehalose. These compounds are optionally desired if they improve the  
10 nutritional value of the product.

These organic substances, including L-methionine and/or D-methionine and/or the racemic mixture D,L-methionine, can also be added, depending on requirements, as a concentrate or pure substance in solid or liquid form during a suitable  
15 process step. These organic substances mentioned can be added individually or as mixtures to the resulting or concentrated fermentation broth, or also during the drying or granulation process. It is likewise possible to add an organic substance or a mixture of several organic  
20 substances to the fermentation broth and a further organic substance or a further mixture of several organic substances during a later process step, for example granulation.

The product described above is suitable as a feedstuffs  
25 additive, i.e. feed additive, for animal nutrition.

The L-methionine content of the animal feedstuffs additive is conventionally 1 wt.% to 80 wt.%, preferably 2 wt.% to 80 wt.%, particularly preferably 4 wt.% to 80 wt.%, and very particularly preferably 8 wt.% to 80 wt.%, based on  
30 the dry weight of the animal feedstuffs additive. Contents of 1 wt.% to 60 wt.%, 2 wt.% to 60 wt.%, 4 wt.% to 60 wt.%, 6 wt.% to 60 wt.%, 1 wt.% to 40 wt.%, 2 wt.% to 40 wt.% or 4 wt.% to 40 wt.% are likewise possible. The water content of the feedstuffs additive is conventionally up to 5 wt.%,

preferably up to 4 wt.%, and particularly preferably less than 2 wt.%.

The invention accordingly also provides a process for the preparation of an L-methionine-containing animal feedstuffs additive from fermentation broths, which comprises the steps

- a) culture and fermentation of an L-methionine-producing microorganism in a fermentation medium;
- b) removal of water from the L-methionine-containing fermentation broth (concentration);
- c) removal of an amount of 0 to 100 wt.% of the biomass formed during the fermentation; and
- d) drying of the fermentation broth obtained according to a) and/or b) to obtain the animal feedstuffs additive in the desired powder or granule form.

If desired, one or more of the following steps can furthermore be carried out in the process according to the invention:

- e) addition of one or more organic substances, including L-methionine and/or D-methionine and/or the racemic mixture D,L-methionine, to the products obtained according to a), b) and/or c);
- f) addition of auxiliary substances chosen from the group consisting of silicas, silicates, stearates, grits and bran to the substances obtained according to a) to d) for stabilization and to increase the storability; or
- g) conversion of the substances obtained according to a) to e) into a form which remains stable in an animal stomach, in particular rumen, by coating with film-forming agents.



The analysis of L-lysine and L-methionine can be carried out by ion exchange chromatography with subsequent ninhydrin derivation, as described by Spackman et al. (Analytical Chemistry, 30, (1958), 1190).

- 5 The following microorganism was deposited as a pure culture on 21.06.2000 at the Deutsche Sammlung für Mikroorganismen und Zellkulturen (DSMZ = German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany) in accordance with the Budapest Treaty:

- 10 • *Corynebacterium glutamicum* strain DSM5715/pCREmetY as DSM 13556

The process according to the invention is used for the fermentative preparation of amino acids, in particular L-lysine and L-methionine.

- 15 The present invention is explained in more detail in the following with the aid of embodiment examples.

Example 1

Preparation of a genomic cosmid gene library from *Corynebacterium glutamicum* ATCC 13032.

- 20 Chromosomal DNA from *Corynebacterium glutamicum* ATCC 13032 was isolated as described by Tauch et al. (1995, Plasmid 33:168-179) and partly cleaved with the restriction enzyme Sau3AI (Amersham Pharmacia, Freiburg, Germany, Product Description Sau3AI, Code no. 27-0913-02). The DNA
- 25 fragments were dephosphorylated with shrimp alkaline phosphatase (Roche Diagnostics GmbH, Mannheim, Germany, Product Description SAP, Code no. 1758250). The DNA of the cosmid vector SuperCos1 (Wahl et al. (1987), Proceedings of the National Academy of Sciences, USA, 84:2160-2164),
- 30 obtained from Stratagene (La Jolla, USA, Product Description SuperCos1 Cosmid Vector Kit, Code no. 251301) was cleaved with the restriction enzyme XbaI (Amersham

Pharmacia, Freiburg, Germany, Product Description XbaI, Code no. 27-0948-02) and likewise dephosphorylated with shrimp alkaline phosphatase.

- The cosmid DNA was then cleaved with the restriction enzyme
- 5 BamHI (Amersham Pharmacia, Freiburg, Germany, Product Description BamHI, Code no. 27-0868-04). The cosmid DNA treated in this manner was mixed with the treated ATCC13032 DNA and the batch was treated with T4 DNA ligase (Amersham Pharmacia, Freiburg, Germany, Product Description T4-DNA-
- 10 Ligase, Code no. 27-0870-04). The ligation mixture was then packed in phages with the aid of Gigapack II XL Packing Extract (Stratagene, La Jolla, USA, Product Description Gigapack II XL Packing Extract, Code no. 200217).
- 15 For infection of the E. coli strain NM554 (Raleigh et al. 1988, Nucleic Acid Research 16:1563-1575) the cells were taken up in 10 mM MgSO<sub>4</sub> and mixed with an aliquot of the phage suspension. The infection and titering of the cosmid library were carried out as described by Sambrook et al. (1989, Molecular Cloning: A laboratory Manual, Cold Spring Harbor), the cells being plated out on LB agar (Lennox, 1955, Virology, 1:190) with 100 mg/l ampicillin. After incubation overnight at 37°C, recombinant individual clones were selected.
- 20

#### Example 2

- 25 Isolation and sequencing of the metY gene

The cosmid DNA of an individual colony was isolated with the Qiaprep Spin Miniprep Kit (Product No. 27106, Qiagen, Hilden, Germany) in accordance with the manufacturer's instructions and partly cleaved with the restriction enzyme

30 Sau3AI (Amersham Pharmacia, Freiburg, Germany, Product Description Sau3AI, Product No. 27-0913-02). The DNA fragments were dephosphorylated with shrimp alkaline phosphatase (Roche Diagnostics GmbH, Mannheim, Germany,

Product Description SAP, Product No. 1758250). After separation by gel electrophoresis, the cosmid fragments in the size range of 1500 to 2000 bp were isolated with the QiaExII Gel Extraction Kit (Product No. 20021, Qiagen, Hilden, Germany).

The DNA of the sequencing vector pZero-1, obtained from Invitrogen (Groningen, The Netherlands, Product Description Zero Background Cloning Kit, Product No. K2500-01) was cleaved with the restriction enzyme BamHI (Amersham Pharmacia, Freiburg, Germany, Product Description BamHI, Product No. 27-0868-04). The ligation of the cosmid fragments in the sequencing vector pZero-1 was carried out as described by Sambrook et al. (1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor), the DNA mixture being incubated overnight with T4 ligase (Pharmacia Biotech, Freiburg, Germany). This ligation mixture was then electroporated (Tauch et al. 1994; FEMS Microbiol. Letters, 123:343-7) into the E. coli strain DH5amcr (Grant, 1990; Proceedings of the National Academy of Sciences U.S.A., 87:4645-4649) and plated out on LB agar (Lennox, 1955, Virology, 1:190) with 50 mg/l zeocin.

The plasmid preparation of the recombinant clones was carried out with Biorobot 9600 (Product No. 900200, Qiagen, Hilden, Germany). The sequencing was carried out by the dideoxy chain termination method of Sanger et al. (1977, Proceedings of the National Academy of Sciences U.S.A., 74:5463-5467) with modifications according to Zimmermann et al. (1990, Nucleic Acids Research, 18:1067). The "RR dRhodamin Terminator Cycle Sequencing Kit" from PE Applied Biosystems (Product No. 403044, Weiterstadt, Germany) was used. The separation by gel electrophoresis and analysis of the sequencing reaction were carried out in a "Rotiphoresis NF Acrylamide/Bisacrylamide" Gel (29:1) (Product No. A124.1, Roth, Karlsruhe, Germany) with the

"ABI Prism 377" sequencer from PE Applied Biosystems (Weiterstadt, Germany).

The raw sequence data obtained were then processed using the Staden program package (1986, Nucleic Acids Research, 14:217-231) version 97-0. The individual sequences of the pZerol derivatives were assembled to a continuous contig. The computer-assisted coding region analysis was prepared with the XNIP program (Staden, 1986, Nucleic Acids Research, 14:217-231).

The resulting nucleotide sequence is shown in SEQ ID No. 1. Analysis of the nucleotide sequence showed an open reading frame of 1313 base pairs, which was called the metY gene. The metY gene codes for a protein of 437 amino acids.

### Example 3

Construction of vectors for expression of metY and metAY

#### 3.1. Amplification of the genes metY and metA

The methionine biosynthesis genes metA and metY from *C. glutamicum* were amplified using the polymerase chain reaction (PCR) and synthetic oligonucleotides. Starting from the nucleotide sequences of the methionine biosynthesis genes metY (SEQ ID No.1) and metA (gene library entry Accession Number AF052652) of *C. glutamicum* ATCC 13032, PCR primers were synthesized (MWG Biotech, Ebersberg, Germany). These primers were chosen so that the amplified fragments contain the genes and native ribosome binding sites thereof, but not possible promoter regions. In addition, suitable restriction cutting sites which allow cloning into the target vector were inserted. The sequences of the PCR primers, the cleavage sites inserted (sequence underlined) and the amplified gene (the fragment size, in bp, is listed in parentheses) are listed in the following Table 1.

Table 1

| Primer    | Sequence with restriction cleavage site                       | Product           | Plasmid  |
|-----------|---|-------------------|----------|
| metY-EVP5 | 5'-CTAATAAGTCGACAAAGGAGGACA<br>Sali<br>ACCATGCCAAAGTACGAC- 3' | metY<br>(1341 bp) | pCREmetY |
| metY-EVP3 | 5'-GAGTCTAATGCATGCTAGATTGCA<br>NsiI<br>GCAAAGCCG 3'           |                   |          |
| metA-EVP5 | 5'-AGAACGAATTCAAAGGAGGACAAC<br>EcoRI<br>CATGCCCACCCCTCGCGC-3' | metA<br>(1161 bp) | pCREmetA |
| metA-EVP3 | 5'-GTCGTGGATCCCTATTAGATGTA<br>PstI<br>GAACTCG-3'              |                   |          |

The PCR experiments were carried out with the Taq DNA polymerase from Gibco-BRL (Eggestein, Germany) in a "PCT-100 Thermocycler" (MJ Research Inc., Watertown, Mass., USA). A single denaturing step of 2 minutes at 94°C was followed by a denaturing step of 90 seconds (sec) at 94°C, an annealing step for 90 sec at a primer-dependent temperature of  $T = (2 \times AT + 4 \times GC) - 5$  C (Suggs, et al., 1981, p. 683-693, In: D.D. Brown, and C.F. Fox (Eds.), Developmental Biology using Purified Genes. Academic Press, New York, USA) and an extension step at 72°C lasting 90 sec. The last three steps were repeated as a cycle 35 times and the reaction was ended with a final extension step of 10 minutes (min) at 72°C. The products amplified in this way were tested electrophoretically in a 0.8% agarose gel.

The metY fragment 1341 bp in size was cleaved with the restriction endonucleases Sali and NsiI, and the metA fragment 1161 bp in size was cleaved with the restriction endonucleases EcoRI and BamHI. The two batches were separated by gel electrophoresis and the fragments metY

(approx. 1330 bp) and metA (approx. 1150 bp) were isolated from the agarose gel with the QiaExII Gel Extraction Kit (Product No. 20021, Qiagen, Hilden, Germany).

### 3.2. Cloning of metY in the vector pZ8-1

5 The E. coli - C. glutamicum shuttle expression vector pZ8-1 (EP 0 375 889) was employed as the base vector for expression both in C. glutamicum and in E. coli. DNA of this plasmid was cleaved completely with the restriction enzymes SalI and PstI and then dephosphorylated with shrimp  
10 alkaline phosphatase (Roche Diagnostics GmbH, Mannheim, Germany, Product Description SAP, Product No. 1758250). The metY fragment isolated from the agarose gel in example 3.1 was mixed with the vector pZ8-1 prepared in this way and the batch was treated with T4 DNA ligase (Amersham  
15 Pharmacia, Freiburg, Germany, Product Description T4-DNA-Ligase, Code no.27-0870-04).

The ligation batch was transformed in the E. coli strain DH5 $\alpha$  (Hanahan, In: DNA cloning. A Practical Approach. Vol. I. IRL-Press, Oxford, Washington DC, USA). Selection of  
20 plasmid-carrying cells was made by plating out the transformation batch on LB agar (Lennox, 1955, Virology, 1:190) with 50 mg/l kanamycin. After incubation overnight at 37°C, recombinant individual clones were selected. Plasmid DNA was isolated from a transformant with the  
25 Qiaprep Spin Miniprep Kit (Product No. 27106, Qiagen, Hilden, Germany) in accordance with the manufacturer's instructions and checked by restriction cleavage. The resulting plasmid was called pCREmetY. It is shown in figure 1.

### 30 3.3. Cloning of metA and metY in the vector pZ8-1

DNA of the plasmid pZ8-1 was cleaved completely with the restriction enzymes EcoRI and BamHI and then dephosphorylated with shrimp alkaline phosphatase (Roche

5 Diagnostics GmbH, Mannheim, Germany, Product Description  
SAP, Product No. 1758250). The metA fragment isolated from  
the agarose gel in example 3.1 was mixed with the vector  
pZ8-1 prepared in this way and the batch was treated with  
T4 DNA ligase (Amersham Pharmacia, Freiburg, Germany,  
Product Description T4-DNA-Ligase, Code no.27-0870-04).

10 The ligation batch was transformed in the E. coli strain  
DH5 $\alpha$  (Hanahan, In: DNA cloning. A Practical Approach. Vol.  
I. IRL-Press, Oxford, Washington DC, USA). Selection of  
plasmid-carrying cells was made by plating out the  
transformation batch on LB agar (Lennox, 1955, Virology,  
1:190) with 50 mg/l kanamycin. After incubation overnight  
at 37°C, recombinant individual clones were selected.  
15 Plasmid DNA was isolated from a transformant with the  
Qiaprep Spin Miniprep Kit (Product No. 27106, Qiagen,  
Hilden, Germany) in accordance with the manufacturer's  
instructions and checked by restriction cleavage. The  
resulting plasmid was called pCREmetA.

20 The plasmid pCREmetA was cleaved completely with the  
restriction enzymes SalI and PstI and then dephosphorylated  
with shrimp alkaline phosphatase (Roche Diagnostics GmbH,  
Mannheim, Germany, Product Description SAP, Product No.  
1758250). The metY fragment isolated from the agarose gel  
in example 3.1 was mixed with the vector pCREmetA prepared  
25 in this way and the batch was treated with T4 DNA ligase  
(Amersham Pharmacia, Freiburg, Germany, Product Description  
T4-DNA-Ligase, Code no.27-0870-04).

The ligation batch was transformed in the E. coli strain  
DH5 $\alpha$  (Hanahan, In: DNA cloning. A Practical Approach. Vol.  
30 I. IRL-Press, Oxford, Washington DC, USA). Selection of  
plasmid-carrying cells was made by plating out the  
transformation batch on LB agar (Lennox, 1955, Virology,  
1:190) with 50 mg/l kanamycin. After incubation overnight  
at 37°C, recombinant individual clones were selected.  
35 Plasmid DNA was isolated from a transformant with the

Qiaprep Spin Miniprep Kit (Product No. 27106, Qiagen, Hilden, Germany) in accordance with the manufacturer's instructions and checked by restriction cleavage. The resulting plasmid was called pCREmetAY. It is shown in figure 2.

#### Example 4

Preparation of the strains DSM5715/pCREmetY and DSM5715/pCREmetAY

The vectors pCREmetY and pCREmetAY mentioned in example 3.2 and 3.3 were electroporated by the electroporation method of Tauch et al. (1994, FEMS Microbiological Letters, 123:343-347) in *Corynebacterium glutamicum* DSM 5715. The strain DSM 5715 is an AEC-resistant lysine producer. Selection for plasmid-carrying cells was made by plating out the electroporation batch on LB agar (Sambrook et al., Molecular Cloning: A Laboratory Manual. 2<sup>nd</sup> Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989), which had been supplemented with 25 mg/l kanamycin. Plasmid DNA was isolated in each case from a transformant by conventional methods (Peters-Wendisch et al., 1998, Microbiology 144, 915-927) and checked by restriction cleavage with subsequent agarose gel electrophoresis. The strains were called DSM5715/pCREmetY and DSM5715pCREmetAY. The strain DSM5715/pCREmetY has been deposited at the Deutsche Sammlung für Mikroorganismen und Zellkulturen (DSMZ = German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany) in accordance with the Budapest Treaty as DSM 13556.

#### Example 5

Preparation of lysine with the strain DSM5715/pCREmetY

The *C. glutamicum* strain DSM5715/pCREmetY obtained in example 4 was cultured in a nutrient medium suitable for



the production of lysine and the lysine content in the culture supernatant was determined.

- For this, the strain was first incubated on an agar plate with the corresponding antibiotic (brain-heart agar with
- 5 kanamycin (50 mg/l)) for 24 hours at 33°C. Starting from this agar plate culture, a pre-culture was seeded (10 ml medium in a 100 ml conical flask). The complete medium CgIII was used as the medium for the pre-culture.

Medium Cg III

NaCl 2.5 g/l

Bacto-Peptide 10 g/l

Bacto-Yeast extract 10 g/l

Glucose (autoclaved separately) 2% (w/v)

The pH was brought to pH 7.4

- 10 Kanamycin (50 mg/l) was added to this. The pre-culture was incubated for 16 hours at 33°C at 240 rpm on a shaking machine. A main culture was seeded from this pre-culture such that the initial OD (660 nm) of the main culture was 0.1. Medium MM was used for the main culture.

## Medium MM

|   |          |
|---|----------|
| CSL (corn steep liquor)                         | 5 g/l    |
| MOPS (morpholinopropanesulfonic acid)           | 20 g/l   |
| Glucose (autoclaved separately)                 | 50 g/l   |
| (NH <sub>4</sub> ) <sub>2</sub> SO <sub>4</sub> | 25 g/l   |
| KH <sub>2</sub> PO <sub>4</sub>                 | 0.1 g/l  |
| MgSO <sub>4</sub> * 7 H <sub>2</sub> O          | 1.0 g/l  |
| CaCl <sub>2</sub> * 2 H <sub>2</sub> O          | 10 mg/l  |
| FeSO <sub>4</sub> * 7 H <sub>2</sub> O          | 10 mg/l  |
| MnSO <sub>4</sub> * H <sub>2</sub> O            | 5.0mg/l  |
| Biotin (sterile-filtered)                       | 0.3 mg/l |
| Thiamine * HCl (sterile-filtered)               | 0.2 mg/l |
| L-Leucine (sterile-filtered)                    | 0.1 g/l  |
| CaCO <sub>3</sub>                               | 25 g/l   |

The CSL, MOPS and the salt solution were brought to pH 7 with aqueous ammonia and autoclaved. The sterile substrate and vitamin solutions were then added, as well as the CaCO<sub>3</sub> autoclaved in the dry state.

Culturing is carried out in a 10 ml volume in a 100 ml conical flask with baffles. Kanamycin (50 mg/l) was added. Culturing was carried out at 33°C and 80% atmospheric humidity.

- 10 After 48 hours, the OD was determined at a measurement wavelength of 660 nm with a Biomek 1000 (Beckmann Instruments GmbH, Munich). The amount of lysine formed was determined with an amino acid analyzer from Eppendorf-

BioTronik (Hamburg, Germany) by ion exchange chromatography and post-column derivation with ninhydrin detection.

The result of the experiment is shown in Table 2.

Table 2

| Strain           | OD(660) | Lysine HCl<br>g/l |
|------------------|---------|-------------------|
| DSM5715          | 10.6    | 15.7              |
| DSM5715/pCREmetY | 9.5     | 16.1              |

5

Example 6

Preparation of methionine with the strain DSM5715/pCREmetAY

10 The *C. glutamicum* strain DSM5715/pCREmetAY obtained in example 4 was cultured in a nutrient medium suitable for the production of methionine and the methionine content in the culture supernatant was determined.

15 For this, the strain was first incubated on an agar plate with the corresponding antibiotic (brain-heart agar with kanamycin (50 mg/l)) for 24 hours at 33°C. Starting from this agar plate culture, a pre-culture was seeded (10 ml medium in a 100 ml conical flask). The complete medium CgIII as described in example 5 was used as the medium for the pre-culture.

20 Kanamycin (50 mg/l) was added to this. The pre-culture was incubated for 16 hours at 33°C at 240 rpm on a shaking machine. A main culture was seeded from this pre-culture such that the initial OD (660 nm) of the main culture was 0.1. The medium MM as described in example 5 was used for the main culture.

The CSL, MOPS and the salt solution were brought to pH 7 with aqueous ammonia and autoclaved. The sterile substrate and vitamin solutions were then added, as well as the  $\text{CaCO}_3$  autoclaved in the dry state.

- 5    Culturing is carried out in a 10 ml volume in a 100 ml conical flask with baffles. Kanamycin (50 mg/l) was added. Culturing was carried out at 33°C and 80% atmospheric humidity.

10    After 72 hours, the OD was determined at a measurement wavelength of 660 nm with a Biomek 1000 (Beckmann Instruments GmbH, Munich). The amount of methionine formed was determined with an amino acid analyzer from Eppendorf-BioTronik (Hamburg, Germany) by ion exchange chromatography and post-column derivatization with ninhydrin detection.

- 15    The result of the experiment is shown in Table 3.

Table 3

| Strain            | OD(660) | Methionine<br>g/l |
|-------------------|---------|-------------------|
| DSM5715           | 6.6     | 1.4               |
| DSM5715/pCREmetAY | 8.3     | 16.0              |

Brief Description of the Figures:

- Figure 1: Plasmid pCREmetY
- 20    ▪ Figure 2: Plasmid pCREmetAY

The abbreviations used in the figures have the following meaning:

Kan:                    Resistance gene for kanamycin

metY: metY gene of *C. glutamicum*

metA: metA gene of *C. glutamicum*

Ptac: tac promoter

rrnB-T1T2: Terminator T1T2 of the rrnB gene of *E. coli*

5 rep: Plasmid-coded replication origin for  
*C. glutamicum* (of pHM1519)

BamHI: Cleavage site of the restriction enzyme BamHI

EcoRI: Cleavage site of the restriction enzyme EcoRI

EcoRV: Cleavage site of the restriction enzyme EcoRV

10 PstI: Cleavage site of the restriction enzyme PstI

Sall: Cleavage site of the restriction enzyme Sall

XhoI: Cleavage site of the restriction enzyme XhoI

What is claimed is:

1. An isolated polynucleotide from coryneform bacteria, comprising a polynucleotide sequence which codes for the metY gene, chosen from the group consisting of
  - 5 a) polynucleotide which is identical to the extent of at least 70% to a polynucleotide which codes for a polypeptide which comprises the amino acid sequence of SEQ ID No. 2,
  - 10 b) polynucleotide which codes for a polypeptide which comprises an amino acid sequence which is identical to the extent of at least 70% to the amino acid sequence of SEQ ID No. 2,
  - c) polynucleotide which is complementary to the polynucleotides of a) or b), and
  - 15 d) polynucleotide comprising at least 15 successive nucleotides of the polynucleotide sequence of a), b) or c),the polypeptide preferably having the activity of O-acetylhomoserine sulphydrylase.
- 20 2. A polynucleotide as claimed in claim 1, wherein the polynucleotide is a preferably recombinant DNA which is capable of replication in coryneform bacteria.
3. A polynucleotide as claimed in claim 1, wherein the polynucleotide is an RNA.
- 25 4. A polynucleotide as claimed in claim 2 or 3, comprising the nucleic acid sequence as shown in SEQ ID No. 1.
5. A DNA as claimed in claim 2 or 3 which is capable of replication, comprising

- (i) the nucleotide sequence shown in SEQ ID No. 1, or
  - (ii) at least one sequence which corresponds to sequence (i) within the range of the degeneration of the genetic code, or
  - 5 (iii) at least one sequence which hybridizes with the sequence complementary to sequence (i) or (ii), and optionally
  - (iv) sense mutations of neutral function in (i).
- 6. A DNA as claimed in claim 5 which is capable of  
10 replication, wherein the hybridization of sequence (iii) is carried out under a stringency corresponding to at most 2x SSC.
  - 7. A polynucleotide sequence as claimed in claim 2 or 3,  
15 which codes for a polypeptide which comprises the amino acid sequence in SEQ ID No. 2.
  - 8. *Corynebacterium glutamicum* strain DSM5715/pCREmetY as  
DSM 13556 deposited at the Deutsche Sammlung für  
Mikroorganismen und Zellkulturen [German Collection of  
Microorganisms and Cell Cultures], Braunschweig,  
20 Germany.
  - 9. A process for the fermentative preparation of L-amino  
acids, in particular L-lysine, which comprises  
carrying out the following steps:
    - 25 a) fermentation of the coryneform bacteria which produce the desired amino acid and in which at least the metY gene or nucleotide sequences which code for it are enhanced, in particular over-expressed;
    - b) concentration of the L-amino acid in the medium or  
30 in the cells of the bacteria; and

- c) isolation of the L-amino acid.
10. A process for the fermentative preparation of L-amino acids, in particular L-methionine, which comprises carrying out the following steps:
- 5 a) fermentation of the L-methionine-producing coryneform bacteria in which the metY gene, optionally with met A, is enhanced, in particular over-expressed;
- 10 b) concentration of the L-amino acid in the medium or in the cells of the bacteria; and
- c) isolation of the L-amino acid.
11. A process as claimed in claim 9 or 10, wherein bacteria in which further genes of the biosynthesis pathway of the desired L-amino acid are additionally enhanced are employed.
- 15 12. A process as claimed in claim 9 or 10, wherein bacteria in which the metabolic pathways which reduce the formation of the desired amino acid are at least partly eliminated are employed.
- 20 13. A process as claimed in claim 9, wherein a strain transformed with a plasmid vector is employed, and the plasmid vector carries the metY gene and optionally additionally the metA gene.
- 25 14. A process as claimed in claim 10, wherein a strain transformed with a plasmid vector is employed, and the plasmid vector carries the nucleotide sequence which codes for the metA and metY genes.
- 30 15. A process as claimed in claim 9, wherein for the preparation of L-amino acids, in particular L-lysine, coryneform microorganisms in which at the same time



one or more of the genes chosen from the group consisting of

15.1 the gap gene which codes for glycerolaldehyde 3-phosphate dehydrogenase,

5 15.2 the tpi gene which codes for triose phosphate isomerase,

15.3 the pgk gene which codes for 3-phosphoglycerate kinase,

10 15.4 the pyc gene which codes for pyruvate carboxylase,

15.5 the lysC gene which codes for a feed back resistant aspartate kinase,

is or are enhanced, in particular over-expressed, are fermented.

15 16. A process as claimed in claim 10, wherein for the preparation of L-amino acids, in particular L-methionine, coryneform microorganisms in which at the same time one or more of the genes chosen from the group consisting of

20 16.1 the lysC gene which codes for a feed back resistant aspartate kinase,

16.2 the gap gene which codes for glycerolaldehyde 3-phosphate dehydrogenase,

25 16.3 the tpi gene which codes for triose phosphate isomerase,

16.4 the metA gene which codes for homoserine O-acetyltransferase,

16.5 the metB gene which codes for cystathionine-gamma-synthase,

16.6 the aecD gene which codes for cystathionine-gamma-lyase,

16.7 the glyA gene which codes for serine hydroxymethyltransferase

5 16.8 the pgk gene which codes for 3-phosphoglycerate kinase

16.9 the pyc gene which codes for pyruvate carboxylase  
is or are enhanced, in particular over-expressed, are fermented.

10 17. A process as claimed in claim 16, wherein for the preparation of L-amino acids, in particular L-methionine, coryneform microorganisms which have an additional enhancement of the metY gene by metA are fermented.

15 18. A process as claimed in claim 9, wherein for the preparation of L-amino acids, in particular L-lysine, coryneform microorganisms which have an additional enhancement of the metY gene by attenuation, in particular reduction in expression, of one or more  
20 genes chosen from the group consisting of

18.1 the pck gene which codes for phosphoenol pyruvate carboxykinase

18.2 the pgi gene which codes for glucose 6-phosphate isomerase

25 18.3 the poxB gene which codes for pyruvate oxidase

are fermented.

19. A process as claimed in claim 10, wherein for the preparation of L-amino acids, in particular L-methionine, coryneform microorganisms in which at the

same time one or more of the genes chosen from the group consisting of

19.1 the thrB gene which codes for homoserine kinase

19.2 the ilvA gene which codes for threonine  
dehydratase

19.3 the thrC gene which codes for threonine synthase

19.4 the ddh gene which codes for meso-diaminopimelate  
D-dehydrogenase

19.5 the pck gene which codes for phosphoenol pyruvate  
carboxykinase

19.6 the pgi gene which codes for glucose 6-phosphate  
isomerase

19.7 the poxB gene which codes for pyruvate oxidase

is or are attenuated or reduced in expression, are  
fermented.

20. A coryneform bacterium in which the metY gene is  
enhanced, in particular over-expressed.

21. A coryneform bacterium which contains a vector which  
carries a polynucleotide as claimed in claim 1.

22. A process as claimed in one or more of claims 9-19,  
wherein microorganisms of the species Corynebacterium  
glutamicum are employed.

23. A process as claimed in claim 22, wherein the  
Corynebacterium glutamicum strain DSM5715/pCREmetY is  
employed.

24. A process as claimed in claim 22, wherein the  
Corynebacterium glutamicum strain DSM5715/pCREmetAY is  
employed.

25. A process for the preparation of an L-methionine-containing animal feedstuffs additive from fermentation broths, which comprises the steps
- 5 a) culture and fermentation of an L-methionine-producing microorganism in a fermentation medium;
  - b) removal of water from the L-methionine-containing fermentation broth (concentration);
  - 10 c) removal of an amount of 0 to 100 wt.% of the biomass formed during the fermentation; and
  - 15 d) drying of the fermentation broth obtained according to b) and/or c) to obtain the animal feedstuffs additive in the desired powder or granule form.
26. A process as claimed in claim 25, wherein
- 15 microorganisms in which further genes of the biosynthesis pathway of L-methionine are additionally enhanced are employed.
27. A process as claimed in claim 26, wherein
- 20 microorganisms in which the metabolic pathways which reduce the formation of L-methionine are at least partly eliminated are employed.
28. A process as claimed in claim 25, wherein the expression of the polynucleotides which code for the metY gene is enhanced, in particular over-expressed.
- 25 29. A process as claimed in one or more of claims 25-28, wherein microorganisms of the species *Corynebacterium glutamicum* are employed.
- 30 30. A process as claimed in claim 29, wherein the *Corynebacterium glutamicum* strain DSM5715/pCREmetY is employed.

31. A process as claimed in claim 29, wherein the *Corynebacterium glutamicum* strain DSM5715/pCREmetAY is employed.
32. A process as claimed in claim 25, wherein one or more of the following steps is or are additionally carried out:
- e) addition of one or more organic substances, including L-methionine and/or D-methionine and/or the racemic mixture D,L-methionine, to the products obtained according to b), c) and/or d);
  - f) addition of auxiliary substances chosen from the group consisting of silicas, silicates, stearates, grits and bran to the substances obtained according to b) to e) for stabilization and to increase the storability; or
  - g) conversion of the substances obtained according to b) to f) into a form which remains stable in an animal stomach, in particular rumen, by coating with film-forming agents.
33. A process as claimed in claim 25 or 32, wherein some of the biomass is removed.
34. A process as claimed in claim 33, wherein up to 100% of the biomass is removed.
35. A process as claimed in claim 25 or 32, wherein the water content is up to 5 wt.%.
36. A process as claimed in claim 35, wherein the water content is less than 2 wt.%.
37. A process as claimed in claim 32, 33, 34, 35 or 36, wherein the film-forming agents are metal carbonates, silicas, silicates, alginates, stearates, starches, gums or cellulose ethers.

38. An animal feedstuffs additive prepared as claimed in claims 25 to 37.
39. An animal feedstuffs additive as claimed in claim 38, which comprises 1 wt.% to 80 wt.% L-methionine, D-methionine, D,L-methionine or a mixture thereof, based on the dry weight of the animal feedstuffs additive.
40. A process for discovering RNA, cDNA and DNA in order to isolate nucleic acids, or polynucleotides or genes which code for O-acetylhomoserine sulphydrolase or have a high similarity with the sequence of the metY gene, which comprises employing the polynucleotide comprising the polynucleotide sequences as claimed in claims 1, 2, 3 or 4 as hybridization probes.

Figure 1: Plasmid pCREmetY





Figure 2: Plasmid pCREmetAY





## SEQUENCE PROTOCOL

&lt;110&gt; Degussa AG

&lt;120&gt; Nucleotide sequences which code for the metY gene

&lt;130&gt; 000053 BT

&lt;140&gt;

&lt;141&gt;

&lt;160&gt; 2

&lt;170&gt; PatentIn Ver. 2.1

&lt;210&gt; 1

&lt;211&gt; 1720

&lt;212&gt; DNA

&lt;213&gt; Corynebacterium glutamicum

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (200)..(1510)

&lt;223&gt; metY gene

&lt;400&gt; 1

```

catcctacac catttagagt ggggctagtc atacccocat aaccctagct gtacgcaatc 60
gatttcaaat cagttggaaa aagtcaagaa aattaccoga gaataaattt ataccacaca 120
gtctattgca atagaccaag ctgttcagta ggggtgcatgg gagaagaatt tcctaataaaa 180
aactottaag gacctccaa atg cca aag tac gac aat tcc aat gct gac cag 232
          Met Pro Lys Tyr Asp Asn Ser Asn Ala Asp Gln
          1             5             10
tgg ggc ttt gaa acc cgc tcc att cac gca ggc cag tca gta gac gca 280
Trp Gly Phe Glu Thr Arg Ser Ile His Ala Gly Gln Ser Val Asp Ala
          15             20             25
cag acc agc gca cga aac ctt ccg atc tac caa tcc acc gct ttc gtg 328
Gln Thr Ser Ala Arg Asn Leu Pro Ile Tyr Gln Ser Thr Ala Phe Val
          30             35             40
ttc gac tcc gct gag cac gcc aag cag cgt ttc gca ctt gag gat cta 376
Phe Asp Ser Ala Glu His Ala Lys Gln Arg Phe Ala Leu Glu Asp Leu
          45             50             55
ggc cct gtt tac tcc cgc ctc acc aac cca acc gtt gag gct ttg gaa 424
Gly Pro Val Tyr Ser Arg Leu Thr Asn Pro Thr Val Glu Ala Leu Glu
          60             65             70             75
aac cgc atc gct tcc ctc gaa ggt ggc gtc cac gct gta gcg ttc tcc 472
Asn Arg Ile Ala Ser Leu Glu Gly Gly Val His Ala Val Ala Phe Ser
          80             85             90

```

|   |      |
|---|------|
| tcc gga cag gcc gca acc acc aac gcc att ttg aac ctg gca gga gcg | 520  |
| Ser Gly Gln Ala Ala Thr Thr Asn Ala Ile Leu Asn Leu Ala Gly Ala |      |
| 95 100 105  |      |
| ggc gac cac atc gtc acc tcc cca cgc ctc tac ggt ggc acc gag act | 568  |
| Gly Asp His Ile Val Thr Ser Pro Arg Leu Tyr Gly Gly Thr Glu Thr |      |
| 110 115 120   |      |
| cta ttc ctt atc act ctt aac cgc ctg ggt atc gat gtt tcc ttc gtg | 616  |
| Leu Phe Leu Ile Thr Leu Asn Arg Leu Gly Ile Asp Val Ser Phe Val |      |
| 125 130 135   |      |
| gaa aac ccc gac gac cct gag tcc tgg cag gca gcc gtt cag cca aac | 664  |
| Glu Asn Pro Asp Asp Pro Glu Ser Trp Gln Ala Ala Val Gln Pro Asn |      |
| 140 145 150 155   |      |
| acc aaa gca ttc ttc ggc gag act ttc gcc aac cca cag gca gac gtc | 712  |
| Thr Lys Ala Phe Phe Gly Glu Thr Phe Ala Asn Pro Gln Ala Asp Val |      |
| 160 165 170   |      |
| ctg gat att cct gcg gtg gct gaa gtt gcg cac cgc aac agc gtt cca | 760  |
| Leu Asp Ile Pro Ala Val Ala Glu Val Ala His Arg Asn Ser Val Pro |      |
| 175 180 185   |      |
| ctg atc atc gac aac acc atc gct acc gca gcg ctc gtg cgc ccg ctc | 808  |
| Leu Ile Ile Asp Asn Thr Ile Ala Thr Ala Ala Leu Val Arg Pro Leu |      |
| 190 195 200   |      |
| gag ctc ggc gca gac gtt gtc gtc gct tcc ctc acc aag ttc tac acc | 856  |
| Glu Leu Gly Ala Asp Val Val Val Ala Ser Leu Thr Lys Phe Tyr Thr |      |
| 205 210 215   |      |
| ggc aac ggc tcc gga ctg ggc ggc gtg ctt atc gac ggc gga aag ttc | 904  |
| Gly Asn Gly Ser Gly Leu Gly Gly Val Leu Ile Asp Gly Gly Lys Phe |      |
| 220 225 230 235   |      |
| gat tgg act gtc gaa aag gat gga aag cca gta ttc ccc tac ttc gtc | 952  |
| Asp Trp Thr Val Glu Lys Asp Gly Lys Pro Val Phe Pro Tyr Phe Val |      |
| 240 245 250   |      |
| act cca gat gct gct tac cac gga ttg aag tac gca gac ctt ggt gca | 1000 |
| Thr Pro Asp Ala Ala Tyr His Gly Leu Lys Tyr Ala Asp Leu Gly Ala |      |
| 255 260 265   |      |
| cca gcc ttc ggc ctc aag gtt cgc gtt ggc ctt cta cgc gac acc ggc | 1048 |
| Pro Ala Phe Gly Leu Lys Val Arg Val Gly Leu Leu Arg Asp Thr Gly |      |
| 270 275 280   |      |
| tcc acc ctc tcc gca ttc aac gca tgg gct gca gtc cag ggc atc gac | 1096 |
| Ser Thr Leu Ser Ala Phe Asn Ala Trp Ala Ala Val Gln Gly Ile Asp |      |
| 285 290 295   |      |
| acc ctt tcc ctg cgc ctg gag cgc cac aac gaa aac gcc atc aag gtt | 1144 |
| Thr Leu Ser Leu Arg Leu Glu Arg His Asn Glu Asn Ala Ile Lys Val |      |
| 300 305 310 315   |      |
| gca gaa ttc ctc aac aac cac gag aag gtg gaa aag gtt aac ttc gca | 1192 |
| Ala Glu Phe Leu Asn Asn His Glu Lys Val Glu Lys Val Asn Phe Ala |      |
| 320 325 330   |      |

ggc ctg aag gat tcc cct tgg tac gca acc aag gaa aag ctt ggc ctg 1240  
 Gly Leu Lys Asp Ser Pro Trp Tyr Ala Thr Lys Glu Lys Leu Gly Leu  
 335 340 345  
 aag tac acc ggc tcc gtt ctc acc ttc gag atc aag ggc ggc aag gat 1288  
 Lys Tyr Thr Gly Ser Val Leu Thr Phe Glu Ile Lys Gly Gly Lys Asp  
 350 355 360  
 gag gct tgg gca ttt atc gac gcc ctg aag cta cac tcc aac ctt gca 1336  
 Glu Ala Trp Ala Phe Ile Asp Ala Leu Lys Leu His Ser Asn Leu Ala  
 365 370 375  
 aac atc ggc gat gtt cgc tcc ctc gtt gtt cac cca gca acc acc acc 1384  
 Asn Ile Gly Asp Val Arg Ser. Leu Val Val His Pro Ala Thr Thr Thr  
 380 385 390 395  
 cat tca cag tcc gac gaa gct ggc ctg gca cgc gcg ggc gtt acc cag 1432  
 His Ser Gln Ser Asp Glu Ala Gly Leu Ala Arg Ala Gly Val Thr Gln  
 400 405 410  
 tcc acc gtc cgc ctg tcc gtt ggc atc gag acc att gat gat atc atc 1480  
 Ser Thr Val Arg Leu Ser Val Gly Ile Glu Thr Ile Asp Asp Ile Ile  
 415 420 425  
 gct gac ctc gaa ggc ggc ttt gct gca atc tagctttaaa tagactcacc 1530  
 Ala Asp Leu Glu Gly Gly Phe Ala Ala Ile  
 430 435  
 ccagtgcctta aagcgctggg tttttctttt tcagactcgt gagaatgcaa actagactag 1590  
 acagagctgt ccatatacac tggacgaagt tttagtcttg tccaccacaga acaggcggtt 1650  
 attttcatgc ccaccctcgc gcottcaggt caacttgaaa tccaagcgat cggatgatgtc 1710  
 tccaccgaag 1720

<210> 2  
 <211> 437  
 <212> PRT  
 <213> Corynebacterium glutamicum

<400> 2  
 Met Pro Lys Tyr Asp Asn Ser Asn Ala Asp Gln Trp Gly Phe Glu Thr  
 1 5 10 15  
 Arg Ser Ile His Ala Gly Gln Ser Val Asp Ala Gln Thr Ser Ala Arg  
 20 25 30  
 Asn Leu Pro Ile Tyr Gln Ser Thr Ala Phe Val Phe Asp Ser Ala Glu  
 35 40 45  
 His Ala Lys Gln Arg Phe Ala Leu Glu Asp Leu Gly Pro Val Tyr Ser  
 50 55 60  
 Arg Leu Thr Asn Pro Thr Val Glu Ala Leu Glu Asn Arg Ile Ala Ser  
 65 70 75 80

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Glu | Gly | Gly | Val | His | Ala | Val | Ala | Phe | Ser | Ser | Gly | Gln | Ala | Ala | 85  | 90  | 95  |
| Thr | Thr | Asn | Ala | Ile | Leu | Asn | Leu | Ala | Gly | Ala | Gly | Asp | His | Ile | Val | 100 | 105 | 110 |
| Thr | Ser | Pro | Arg | Leu | Tyr | Gly | Gly | Thr | Glu | Thr | Leu | Phe | Leu | Ile | Thr | 115 | 120 | 125 |
| Leu | Asn | Arg | Leu | Gly | Ile | Asp | Val | Ser | Phe | Val | Glu | Asn | Pro | Asp | Asp | 130 | 135 | 140 |
| Pro | Glu | Ser | Trp | Gln | Ala | Ala | Val | Gln | Pro | Asn | Thr | Lys | Ala | Phe | Phe | 145 | 150 | 155 |
| Gly | Glu | Thr | Phe | Ala | Asn | Pro | Gln | Ala | Asp | Val | Leu | Asp | Ile | Pro | Ala | 165 | 170 | 175 |
| Val | Ala | Glu | Val | Ala | His | Arg | Asn | Ser | Val | Pro | Leu | Ile | Ile | Asp | Asn | 180 | 185 | 190 |
| Thr | Ile | Ala | Thr | Ala | Ala | Leu | Val | Arg | Pro | Leu | Glu | Leu | Gly | Ala | Asp | 195 | 200 | 205 |
| Val | Val | Val | Ala | Ser | Leu | Thr | Lys | Phe | Tyr | Thr | Gly | Asn | Gly | Ser | Gly | 210 | 215 | 220 |
| Leu | Gly | Gly | Val | Leu | Ile | Asp | Gly | Gly | Lys | Phe | Asp | Trp | Thr | Val | Glu | 225 | 230 | 235 |
| Lys | Asp | Gly | Lys | Pro | Val | Phe | Pro | Tyr | Phe | Val | Thr | Pro | Asp | Ala | Ala | 245 | 250 | 255 |
| Tyr | His | Gly | Leu | Lys | Tyr | Ala | Asp | Leu | Gly | Ala | Pro | Ala | Phe | Gly | Leu | 260 | 265 | 270 |
| Lys | Val | Arg | Val | Gly | Leu | Leu | Arg | Asp | Thr | Gly | Ser | Thr | Leu | Ser | Ala | 275 | 280 | 285 |
| Phe | Asn | Ala | Trp | Ala | Ala | Val | Gln | Gly | Ile | Asp | Thr | Leu | Ser | Leu | Arg | 290 | 295 | 300 |
| Leu | Glu | Arg | His | Asn | Glu | Asn | Ala | Ile | Lys | Val | Ala | Glu | Phe | Leu | Asn | 305 | 310 | 315 |
| Asn | His | Glu | Lys | Val | Glu | Lys | Val | Asn | Phe | Ala | Gly | Leu | Lys | Asp | Ser | 325 | 330 | 335 |
| Pro | Trp | Tyr | Ala | Thr | Lys | Glu | Lys | Leu | Gly | Leu | Lys | Tyr | Thr | Gly | Ser | 340 | 345 | 350 |
| Val | Leu | Thr | Phe | Glu | Ile | Lys | Gly | Gly | Lys | Asp | Glu | Ala | Trp | Ala | Phe | 355 | 360 | 365 |
| Ile | Asp | Ala | Leu | Lys | Leu | His | Ser | Asn | Leu | Ala | Asn | Ile | Gly | Asp | Val | 370 | 375 | 380 |
| Arg | Ser | Leu | Val | Val | His | Pro | Ala | Thr | Thr | Thr | His | Ser | Gln | Ser | Asp | 385 | 390 | 395 |
|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | 400 |

Glu Ala Gly Leu Ala Arg Ala Gly Val Thr Gln Ser Thr Val Arg Leu  
405 410 415

Ser Val Gly Ile Glu Thr Ile Asp Asp Ile Ile Ala Asp Leu Glu Gly  
420 425 430

Gly Phe Ala Ala Ile  
435

# INTERNATIONAL SEARCH REPORT

International Application No

PC 1, EP 01/08223

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12P13/12 C07K14/34 C12N9/00 C12N1/21 C12N15/10  
C12N15/63 C12Q1/68 A23L1/305 //(C12P13/12, C12R1:15)

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12P C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, SEQUENCE SEARCH, EMBASE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages                | Relevant to claim No. |
|------------|---|-----------------------|
| X          | DATABASE EMBL 'Online!<br>Accession Number AF052652,<br>20 March 1998 (1998-03-20)<br>XP002185275 | 1-8, 20,<br>21, 40    |
| Y          | the whole document  | 9-19,<br>22-39        |
| X          | DATABASE EMBL 'Online!<br>Accession Number AF109162,<br>9 June 1999 (1999-06-09)<br>XP002185276   | 1-3, 5, 6,<br>21, 40  |
| Y          | the whole document  | 9-19,<br>22-39        |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex

### \* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*A\* document member of the same patent family

Date of the actual completion of the international search

4 January 2002

Date of mailing of the international search report

22/01/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Chavanne, F

# INTERNATIONAL SEARCH REPORT

International Application No  
PC/EP 01/08223

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No.     |
|------------|---|---------------------------|
| X          | YAMAGATA: "Roles of O-acetyl-L-homoserine sulhydrylases in micro-organisms"<br>BIOCHIMIE,<br>vol. 71, 1989, pages 1125-1143,<br>XP002185274   | 1-8, 40                   |
| Y          | abstract<br>page 1136, column 1 -page 1137, column 2  | 9-39                      |
| X          | DE 196 44 567 A (KERNFORSCHUNGSANLAGE<br>JUELICH ;HOLLAND SWEETENER CO (NL))<br>30 April 1998 (1998-04-30)  | 5, 6                      |
| Y          | abstract<br><br>page 2, line 1 - line 3<br>page 3, line 9<br>page 3, line 18 - line 20<br>page 3, line 27 - line 30<br>page 3, line 36 - line 38<br>page 4, line 46 -page 5, line 6<br>page 6, line 45 - line 53<br>example 1<br>claims 1, 5, 14-19 | 9-19,<br>22-39            |
| X          | EP 0 387 527 A (DEGUSSA)<br>19 September 1990 (1990-09-19)  | 5, 6                      |
| Y          | abstract<br>page 2, line 9 - line 38<br>table 2   | 9-39                      |
| X          | EP 0 219 027 A (KYOWA HAKKO KOGYO KK)<br>22 April 1987 (1987-04-22)   | 5, 6                      |
| Y          | page 1, line 27 -page 2, line 2<br>page 3, line 6 - line 16<br>page 6, line 23 - line 32  | 9-39                      |
| Y          | US 3 729 381 A (NAKAYAMA K ET AL)<br>24 April 1973 (1973-04-24)<br>the whole document   | 9-24                      |
| X          | WO 93 17112 A (GENENCOR INT)<br>2 September 1993 (1993-09-02)   | 5, 6                      |
| Y          | abstract<br><br>page 1, line 1 -page 2, line 2; examples<br>1-7   | 9, 10,<br>20-23,<br>25-39 |
|            | ---   |                           |
|            | ---<br>-/-  |                           |

## INTERNATIONAL SEARCH REPORT

International Application No  
PC 1/EP 01/08223

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No.    |
|------------|---|--------------------------|
| X          | DATABASE WPI<br>Section Ch, Week 199332<br>Derwent Publications Ltd., London, GB;<br>Class B05, AN 1993-256072<br>XP002186600<br>& KR 9 208 381 B (CHEIL SUGAR CO),<br>26 September 1992 (1992-09-26)   | 5,6                      |
| Y          | abstract  | 9,10,<br>20-23,<br>25-39 |
| P,X        | -----<br>DATABASE WPI<br>Section Ch, Week 200114<br>Derwent Publications Ltd., London, GB;<br>Class B04, AN 2001-137957<br>XP002186601<br>& WO 01 00843 A (BASF AG),<br>4 January 2001 (2001-01-04)<br>the whole document   | 1-40                     |
| P,X        | -----<br>DATABASE EMBL 'Online!<br>Accession Number AF220150,<br>17 January 2001 (2001-01-17)<br>XP002185277<br>the whole document  | 1-8,20,<br>21,40         |
| P,X        | -----<br>EP 1 108 790 A (KYOWA HAKKO KOGYO KK)<br>20 June 2001 (2001-06-20)<br>abstract<br>table 1<br>SEQ ID No.726   | 1-8,20,<br>21,40         |
| A          | -----<br>KRAMER R: "Genetic and physiological<br>approaches for the production of amino<br>acids", JOURNAL OF BIOTECHNOLOGY,<br>ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM,<br>NL, VOL. 45, NR. 1, PAGE(S) 1-21<br>XP004036833<br>ISSN: 0168-1656<br>the whole document |                          |
| A          | -----<br>EIKMANN B J ET AL: "MOLECULAR ASPECTS OF<br>LYSINE, THREONINE, AND ISOLEUCINE<br>BIOSYNTHESIS IN CORYNEBACTERIUM<br>GLUTAMICUM", ANTONIE VAN LEEUWENHOEK,<br>DORDRECHT, NL, VOL. 64, NR. 2, PAGE(S)<br>145-163 XP000918559<br>the whole document<br>-----  |                          |



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PC 1/cP 01/08223

| Patent document cited in search report |   | Publication date | Patent family member(s) | Publication date |
|--|---|------------------|-------------------------|------------------|
| DE 19644567                            | A | 30-04-1998       | DE 19644567 A1          | 30-04-1998       |
|  |   |                  | AU 4727897 A            | 22-05-1998       |
|  |   |                  | WO 9818937 A1           | 07-05-1998       |
| EP 0387527                             | A | 19-09-1990       | DE 3908201 A1           | 27-09-1990       |
|  |   |                  | AT 107699 T             | 15-07-1994       |
|  |   |                  | DE 59006167 D1          | 28-07-1994       |
|  |   |                  | EP 0387527 A1           | 19-09-1990       |
|  |   |                  | ES 2056263 T3           | 01-10-1994       |
|  |   |                  | JP 3000087 B2           | 17-01-2000       |
|  |   |                  | JP 3219885 A            | 27-09-1991       |
|  |   |                  | SK 122890 A3            | 11-02-1999       |
| EP 0219027                             | A | 22-04-1987       | JP 1984589 C            | 25-10-1995       |
|  |   |                  | JP 6102028 B            | 14-12-1994       |
|  |   |                  | JP 62079788 A           | 13-04-1987       |
|  |   |                  | DE 219027 T1            | 05-11-1987       |
|  |   |                  | EP 0219027 A2           | 22-04-1987       |
| US 3729381                             | A | 24-04-1973       | JP 55040240 B           | 16-10-1980       |
|  |   |                  | CA 952050 A1            | 30-07-1974       |
|  |   |                  | DE 2105189 A1           | 12-08-1971       |
|  |   |                  | FR 2078171 A5           | 05-11-1971       |
|  |   |                  | GB 1338434 A            | 21-11-1973       |
| WO 9317112                             | A | 02-09-1993       | CA 2130347 A1           | 02-09-1993       |
|  |   |                  | EP 0630406 A1           | 28-12-1994       |
|  |   |                  | JP 7503855 T            | 27-04-1995       |
|  |   |                  | WO 9317112 A1           | 02-09-1993       |
| KR 9208381                             | B | 26-09-1992       | KR 9208381 B1           | 26-09-1992       |
| WO 0100843                             | A | 04-01-2001       | AU 5421300 A            | 31-01-2001       |
|  |   |                  | WO 0100843 A2           | 04-01-2001       |
|  |   |                  | AU 5559000 A            | 31-01-2001       |
|  |   |                  | WO 0100844 A2           | 04-01-2001       |
|  |   |                  | AU 5836900 A            | 31-01-2001       |
|  |   |                  | WO 0100804 A2           | 04-01-2001       |
|  |   |                  | AU 5421600 A            | 31-01-2001       |
|  |   |                  | WO 0100805 A2           | 04-01-2001       |
|  |   |                  | AU 5420500 A            | 31-01-2001       |
|  |   |                  | WO 0100842 A2           | 04-01-2001       |
| EP 1108790                             | A | 20-06-2001       | EP 1108790 A2           | 20-06-2001       |

**THIS PAGE BLANK (USPTO)**

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**